Please assess the completion status of the following clinical trial:

Trial Title: Immunotherapy in Treating Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed metastatic breast cancer that expresses carcinoembryonic antigen (CEA)~  * At least 25% of the tumor cells must stain positive for CEA with at least moderate intensity~* Must have achieved either partial response or complete response after high dose chemotherapy and peripheral blood stem cell transplant~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Menopausal status:~* Not specified~Performance status:~* Karnofsky 70-100%~Life expectancy:~* Greater than 6 months~Hematopoietic:~* Absolute neutrophil count at least 1000/mm\^3~* Absolute lymphocyte count at least 1000/mm\^3~* Hemoglobin at least 9 mg/dL~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin less than 2.0 mg/dL~* No serious ongoing chronic or acute hepatic disease~Renal:~* Creatinine less than 2.5 mg/dL~Cardiovascular:~* No serious ongoing chronic or acute cardiac disease (New York Heart Association class III or IV)~Pulmonary:~* No serious ongoing chronic or acute pulmonary illness such as asthma, chronic obstructive pulmonary disease, or radiation or drug induced pneumonitis~Other:~* No other prior or concurrent malignancy except nonmelanoma skin cancer or controlled superficial bladder cancer within the past 5 years~* No history of autoimmune disease such as inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, scleroderma, or multiple sclerosis~* No inflammatory bowel condition such as active infectious enteritis or eosinophilic enteritis~* No active acute or chronic infection such as urinary tract infection, HIV, or viral hepatitis~* Not pregnant or nursing~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Disease Characteristics~* No concurrent immunotherapy~Chemotherapy:~* See Disease Characteristics~* No concurrent chemotherapy~Endocrine therapy:~* At least 4 weeks since steroids~* No concurrent steroid therapy~Radiotherapy:~* No concurrent radiotherapy~Surgery:~* Not specified~Other:~* No concurrent immunosuppressive agents such as azathioprine or cyclosporine A

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- carcinoembryonic antigen RNA-pulsed DC cancer vaccine (Type: EXPERIMENTAL): carcinoembryonic antigen RNA-pulsed DC cancer vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).